Burr bill, Novartis makeover, ALS update: a BioCentury podcast

Sen. Richard Burr’s new approach to a critical medical products user fee bill funding FDA must be taken seriously because the clock is ticking, and it’s ticking loudly, Washington Editor Steve Usdin said on the latest BioCentury This Week podcast. Usdin explains why Burr has introduced the bare-bones legislation and what’s at stake for industry in the weeks ahead. 

Usdin and colleagues also discuss FDA’s neurodegeneration blueprint, clinical updates in ALS from  Clene Inc. (NASDAQ:CLNN) and base editing from  Verve Therapeutics Inc. (NASDAQ:VERV), and plans to reshape Novartis AG (SIX:NOVN; NYSE:NVS).

This week’s podcast was sponsored by the BioCentury-BayHelix East-West Summit 2022, a gathering of biopharma executives and investors focused on building trusted cross-border relationships across the biopharma ecosystem. The VIP event takes place in the San Francisco Bay Area Nov. 14-16. For information on how to sponsor BioCentury This Week and The BioCentury Show, please contact Sarah Shoaff at sarah.shoaff@biocentury.com.